CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) designed to boost growth hormone and insulin-like growth factor 1 (IGF-1) levels in the plasma. The addition of DAC extends the plasma half-life of CJC-1295.
Product is injectable, in powder form, needs reconstitution before use. Please read more on our FAQ page.
SHARE:
Products sold on our website are designed for in vitro testing and lab experimentation exclusively.
All the products you see on the website are being sold in a lyophilized powder state (freeze-dried), in a sealed sterile vial; and should be reconstituted.
The product’s label clearly states the amount of product a vial contains; some products are offered in different variations.
The products we are selling come in a sealed vial but require additional lab equipment for proper testing.
Numerous modifications have been made to growth hormone-releasing hormone (GHRH) to develop analogues that retain certain effects while eliminating others. Among these modifications is CJC-1295, which comprises only the first 29 amino acids of GHRH. This analog, specifically a maleimido derivative of hGRF(1-29), was designed to create a more soluble GH secretagogue, facilitating easier production in large quantities, while still maintaining the beneficial physiological actions of GHRH.
CJC-1295 is a modified form of the first 29 amino acids of GHRH, making it chemically akin to other GHRH analogues, such as Sermorelin. Although it shares considerable similarities with modified GRF (1-29), the two peptides are not entirely identical. The resemblance between these peptides often leads to confusion, especially due to the original addition of a chemical compound called the drug affinity complex (DAC) in CJC-1295.
DAC is integrated into the molecule using a lysine linker to provide protection while the peptide circulates in the bloodstream. By enabling the peptide to bind to the common blood protein albumin, DAC ensures that the half-life of CJC-1295 is significantly extended compared to similar molecules like GRF (1-29).
Half-life of CJC-1295-DAC compared to standard growth hormone releasing factor (GRF)
Source: Oxford Academic
Initially, ConjuChem Biotechnologies, the developer of DAC, labeled the molecule containing DAC as CJC-1295. However, confusion arose as they also offered the peptide without DAC. To clarify, the version containing DAC is now called CJC-1295-DAC, and the one without DAC is referred to as CJC-1295 or CJC-1295-no DAC.
Source: Oxford Academic
Source: Oxford Academic
As a derivative of GHRH, it's expected that CJC-1295 would stimulate GH release. Studies indicate that a single dose of CJC-1295 can increase GH levels in mice by 2-10 times. Peak GH levels are typically reached about 2 hours after administration, and the effects can last for approximately six days. What sets CJC-1295 apart from other GH secretagogues is its ability to maintain the normal physiological release of GH[1]. This means that the natural peaks and valleys of GH release throughout the day remain unaffected, making CJC-1295 a physiologic growth hormone-releasing factor.
Maintaining the natural GH release pattern while enhancing the hormone's concentration in the bloodstream is crucial for achieving heightened effects without increased side effects. Notably, CJC-1295 has been shown to preserve GH's physiological impact on hyperplasia, hypertrophy, bone density, blood sugar regulation, fat metabolism, protein synthesis, and myocardial (heart cell) function.
Research conducted on mice lacking normal GHRH physiology has revealed that CJC-1295 maintains the regular release of growth hormone (GH)[2]. This characteristic makes the peptide a potentially valuable therapy for addressing abnormal growth in various mammalian species, including humans. Preserving the normal pulsatile release of GH is crucial to ensure the appropriate secretion of downstream hormones, such as insulin-like growth factor-2 (IGF-1).
Early 1990s research suggests that CJC-1295 and similar GH-releasing factor (GRF) analogues could have potential in promoting ovulation among infertile female patients. Scientists have recognized the role of insulin-like growth factor-1 (IGF-1) in ovulation and its likely connection to growth hormone (GH) release and cycling. Studies in animal models of superovulation support these theories, demonstrating significant increases in both GH and IGF-1 levels during ovulation. Moreover, administration of GH secretagogues, such as CJC-1295, has shown to induce appropriate ovulation[3]. There is also speculation about the potential application of CJC-1295 and similar analogues in male infertility to regulate sperm production, although this hypothesis has yet to be tested.
CJC-1295 is a growth hormone secretagogue specifically designed to have a prolonged plasma half-life and preserve the natural patterns of the GH axis. It has succeeded in both aspects, making it a promising molecule. While initial interest in research settings was limited due to the emergence of similar compounds and the proprietary nature of its structure, the ability to now manufacture CJC-1295 with ease is likely to rekindle interest in its properties, especially in addressing the increasingly challenging issue of human infertility.
CJC-1295 has demonstrated moderate side effects, low oral bioavailability, and excellent subcutaneous bioavailability in mice. However, it's important to note that the dosage per kilogram in mice does not directly translate to humans. Therefore, any usage of CJC-1295 for research purposes must be strictly limited to educational and scientific research, as it is not intended for human consumption. Researchers must ensure that they are licensed before obtaining and using CJC-1295.
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Dr. Dominique Bridon holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor. He completed his Post-Doctoral Research at the University of California, Berkeley. He studied the potential of CJC-1295 as a long lasting GRF analog and also held various leadership positions involving peptide research and technologies at Ipsen, Conjuchem, Redcell, and Abbott Laboratories. Dr. Bridon has served as a Director for Enobia (acquired by Alexion) and Neuronax and as a member of the Scientific Advisory Board of Syntaxin (acquired by Ipsen) and Biosortia. He now brings 30 years of executive and scientific leadership experience to the Epivax Oncology team.
Dr. Dominique Bridon is being referenced as one of the leading scientists involved in the research and development of CJC-1295. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Shop and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Dominique Bridon is listed in [4] under the referenced citations.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
Useful links
Our support team is at your service, ensuring customer satisfaction.
Our support team is at your service, ensuring customer satisfaction.
